Work

531. GM-1020 is a Novel, Orally Bioavailable NMDA Antagonist With Improved Separation Between Antidepressant and Ataxic Doses Compared to Ketamine

Year: 2023

Type: article

Source: Biological Psychiatry

DOI: 10.1016/j.biopsych.2023.02.771

Authors: Adam Klein, Dino Dvorak, Eric Austin, Gerard Marek, Jonathan Sporn, Zoe Hughes, Laszlo Kiss, Andrew Kruegel

Institution: Gilgamesh Pharma (United States)

Language: English

Topic: Treatment of Major Depression

Subfield: Pharmacology (medical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4363673471

FWCI:

Cites:

Cited by:

Related to: 10